Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Proinflammation in human tumor microenvironment: its status and implication

Masakazu Toi

    Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
    |August 13, 2002
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Clinical Experience with Simultaneous Mixed Infusion of Trastuzumab and Pertuzumab in the Neo-Peaks Study (JBCRG-20 Sub-Study).

    Gan to kagaku ryoho. Cancer & chemotherapy·2024
    Same author

    Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors.

    Cancer science·2024
    Same author

    Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.

    Breast cancer (Tokyo, Japan)·2024
    Same author

    Automated System to Capture Patient Symptoms From Multitype Japanese Clinical Texts: Retrospective Study.

    JMIR medical informatics·2024
    Same author

    A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer.

    Future oncology (London, England)·2024
    Same author

    Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.

    The Lancet. Oncology·2024